SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Preventive Visit — Gilda Radner

PatientGilda Radner
Date of birth1986-06-28
IdentifiersMRN HR-ML026-SYN; SSN (made up) 000-26-8821
Document date2026-10-13
AuthorDelia Marchand, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit, four weeks into olaparib. [S]

History of Present Illness

Ms. Radner, now 40, comes for her yearly preventive visit four weeks after starting olaparib maintenance. She finished six cycles of carboplatin and paclitaxel seven weeks ago; the end-of-treatment CT showed no evidence of disease and her CA-125 was 9. On olaparib she has mild nausea in the first hour after the morning dose, which settles if she takes it with food, and she tires in the late afternoon. She has no breathlessness, cough, fever, or bruising. The tingling in her toes is fading. Hot flashes wake her two or three nights a week; she has chosen to wait on hormone therapy for now. She goes to a support group at a cancer support community every other week and is writing again. Her PHQ-9 today is 2. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 40
Active conditionsStage IIIC high-grade serous ovarian cancer, no evidence of disease after surgery and chemotherapy; on olaparib for four weeks
MedicinesOlaparib 300 mg twice daily; ondansetron when needed, used twice this month
Olaparib effectsMild morning nausea, afternoon tiredness; no breathlessness or bruising
MenopauseHot flashes two or three nights a week; hormone therapy deferred by her choice
MoodPHQ-9 2; attends a support group

Health risk assessment. Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Marchand. [S]

DomainFinding
Self-rated healthGood and improving
PsychosocialSupported by her spouse and friends; a support group every other week; back to writing and some work
TobaccoNever smoked
Alcohol and drugsA glass of wine on some weekends (AUDIT-C 1); no drugs
Physical activityWalks 30 minutes most days; building up after treatment
NutritionThree small meals and snacks; appetite back; weight up 1.4 kg since the end of chemotherapy
SleepSix to seven hours, broken by hot flashes two or three nights a week
Sexual healthVaginal dryness since surgery; using a moisturizer
Safety at homeFeels safe; no one hurts, threatens, or controls her; no firearm in the home
Road safetyWears a seat belt
Activities of daily livingIndependent

Review of Systems

SystemResultFinding
ConstitutionalPositiveAfternoon tiredness; no fever, night sweats, or weight loss
EyesNegativeNo vision change
Ears, nose, mouth, and throatNegativeNo mouth sores or hearing change
CardiovascularNegativeNo chest pain, palpitations, or leg swelling
RespiratoryNegativeNo cough or breathlessness
GastrointestinalPositiveMild nausea after the morning dose; no bloating, early fullness, or change in bowel habit
GenitourinaryPositiveVaginal dryness; no urinary symptoms or vaginal bleeding
MusculoskeletalNegativeNo joint or bone pain
IntegumentaryNegativeHair growing back; no rash or bruising
NeurologicalPositiveSlight tingling in the toes, fading; no weakness or falls
EndocrinePositiveHot flashes two or three nights a week
PsychiatricNegativeMood good; PHQ-9 2; no thoughts of self-harm
Hematologic and lymphaticNegativeNo bruising, bleeding, or swollen glands

13 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery40 mg under the skin once daily for 28 daysSubcutaneous route2026-04-21 to 2026-05-18completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-04-21 to 2026-05-05completedS
Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2026-05-12 to 2026-08-25completedS
Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidineDay 1 every 21 days for six cyclesIntravenous route2026-05-12 to 2026-08-25completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as needed for nauseaOral route2026-05-12activeS
Olaparib 150 mg oral tablet, two tablets (300 mg) by mouth twice daily with food, as maintenance for up to two yearsTwo tablets twice daily with foodOral route2026-09-15activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-13Body height160cmS
2026-10-13Body weight57.2kgS
2026-10-13Body mass index (BMI) [Ratio]22.3kg/m2S
2026-10-13Systolic blood pressure112mm[Hg]S
2026-10-13Diastolic blood pressure70mm[Hg]S
2026-10-13Heart rate74/minS
2026-10-13Respiratory rate14/minS
2026-10-13Body temperature36.6CelS
2026-10-13Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-13Hemoglobin [Mass/volume] in Blood10.6g/dL11.6-15 g/dLLowS
2026-10-13Leukocytes [#/volume] in Blood by Automated count4.210*3/uL4-11 10*3/uLNormalS
2026-10-13Neutrophils [#/volume] in Blood by Automated count2.410*3/uL1.5-7.7 10*3/uLNormalS
2026-10-13Platelets [#/volume] in Blood by Automated count18210*3/uL150-400 10*3/uLNormalS
2026-10-13Cholesterol [Mass/volume] in Serum or Plasma186mg/dL<=200 mg/dLNormalS
2026-10-13Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=50 mg/dLNormalS
2026-10-13Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation108mg/dL<=129 mg/dLNormalS
2026-10-13Triglyceride [Mass/volume] in Serum or Plasma98mg/dL<=149 mg/dLNormalS
2026-10-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-10-13Total score [AUDIT-C]1{score}S

Physical Exam

Vital signs recorded on 2026-10-13; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell; weight 57.2 kg, BMI 22.3; blood pressure 112/70
Head, eyes, ears, nose, and throatNo mouth ulcers; short regrowing hair
NeckThyroid normal; no lymph nodes
BreastsNo mass, skin change, or nipple discharge on either side; no axillary nodes
CardiovascularRegular rhythm; no murmur; no leg swelling
RespiratoryClear to auscultation bilaterally
AbdomenMidline scar healed; soft, non-tender, no mass, no fluid
Lymph nodesNo cervical, supraclavicular, axillary, or inguinal nodes
NeurologicalLight touch slightly reduced over the tips of the toes; vibration sense and ankle reflexes normal; steady gait
SkinNo rash, bruising, or suspicious lesions
PsychiatricBright and funny; organized; engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the weekresolvedconfirmed R19.00S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation.
High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian canceractiveconfirmed C56.3S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D).
Peritoneal and omental metastases of the ovarian cancer, with ascitesactiveconfirmed C78.6S — Synthetic extent of disease on CT and biopsy.
Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is knownactiveconfirmed Z80.41S — Synthetic coding of her documented family history; the basis for genetic counseling.
Acute viral upper respiratory infection on day 8 of the second chemotherapy cycle: two days of sore throat, runny nose and a dry cough, without fever; rapid influenza and COVID-19 tests negative; resolvedresolvedconfirmed J06.9S — Synthetic acute infection; not a historical claim.
Symptomatic surgical menopause after bilateral salpingo-oophorectomy at 39: hot flashes and night sweatsactiveconfirmed E89.41S — Synthetic consequence of the synthetic operation.
Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes and fingertips, grade 1 (sensory only, no effect on daily activities)activeconfirmed G62.0S — Synthetic common effect of paclitaxel.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today112/70 mmHg
Depression screeningCompleted todayPHQ-9 score 2; item 9 scored 0
Unhealthy alcohol use screeningCompleted todayAUDIT-C score 1
Tobacco useCompleted todayNever smoked
Intimate partner violence screeningCompleted todayNegative; she feels safe
Breast cancer screeningOrderedScreening mammogram every two years from 40; first one ordered today. Her germline panel was negative, so no extra breast imaging is needed for a variant
Cervical cancer screeningNot indicatedCervix removed at a hysterectomy for ovarian cancer, with no history of cervical precancer
Colorectal cancer screeningNot indicatedStarts at 45; no family history of bowel cancer; Lynch syndrome genes negative on her panel
Cholesterol screening and statin decisionCompleted todayTotal cholesterol 186, HDL 58, LDL 108 mg/dL; ten-year risk under 2 percent; no statin
Diabetes screeningNot indicatedBMI 22.3 with no other risk factor
Osteoporosis screeningOrderedPostmenopausal after surgery at 39, so a baseline bone density scan is reasonable
Hepatitis B, hepatitis C and HIV screeningUp to dateAll negative before chemotherapy
Ovarian cancer screeningNot indicatedScreening is for women without symptoms; she is under cancer surveillance with gynecologic oncology
Influenza vaccineCompleted todayInactivated vaccine given
COVID-19 vaccineCompleted todayThis season's mRNA vaccine given
Pneumococcal vaccineCompleted todayPCV20 given, for an adult under 50 after cancer chemotherapy
Recombinant zoster vaccineCompleted todayDose 1 given, for an adult under 50 after cancer chemotherapy; dose 2 in two to six months
Tetanus, diphtheria, and pertussisUp to dateTdap five years ago
Live vaccines (MMR, varicella)Not indicatedImmune from childhood doses; live vaccines are avoided within three months of chemotherapy
Dental examinationDueLast visit before chemotherapy; to book a cleaning now that counts have recovered

Immunizations given today: Influenza vaccine, this season (inactivated); COVID-19 mRNA vaccine, this season's formula; Pneumococcal conjugate vaccine (PCV20); Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-3493 (2020); Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Breast Cancer: Screening (2024); Adult Immunization Schedule by Medical Condition and Other Indication (2026)

Follow-up: Mammogram and bone density scan within the month. Blood count in four weeks. Gynecologic oncology review in about five weeks. Second zoster dose in two to six months. Next preventive visit in one year. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 20 minutes, with her consent. She named a health care agent, recorded in the confidential part of the chart and not named here. She said that she wants to be told the truth about her illness plainly and in person, that she would want treatment aimed at living longer as long as she can still enjoy her days and be herself, and that if that were no longer possible she would want comfort and to be awake enough to know the people around her. She completed a health care proxy form and will think about a written living will. To be revisited at each change in her health and at least yearly. [S]